Please assess the completion status of the following clinical trial:

Trial Title: Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female gender;~* Age ≥18 years;~* Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1~* Histologically confirmed invasive breast cancer:~* Primary tumour greater than 2 cm diameter, measured by clinical examination and mammography or echography,~* Any N,~* No evidence of metastasis (M0) (isolated supraclavicular node involvement allowed);~* Over expression and/or amplification of HER2 in the invasive component of the primary tumour \[Wolff et al 2006\] and confirmed by a certified laboratory prior to randomisation~* Known hormone receptor status.~* Haematopoietic status:~* Absolute neutrophil count ≥ 1,5 x 10\^9/L,~* Platelet count ≥ 100 x 10\^9/L,~* Hemoglobin at least 9 g/dl,~* Hepatic status:~* Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\< 2 x ULN) is allowed,~* Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 times ULN,~* Alkaline phosphatase ≤ 2.5 times ULN,~* Renal status:~* Creatinine ≤ 2.0 mg/dL,~* Cardiovascular:~* Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan,~* Negative serum pregnancy test, within 2-weeks (preferably 7 days) prior to randomization (For women of childbearing potential)~* Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed)~* Signed informed consent form (ICF)~* Patient accepts to make available tumour samples for submission to central laboratory to conduct translational studies as part of this protocol~Exclusion Criteria:~* Received any prior treatment for primary invasive breast cancer;~* Previous (less than 10 years) or current history of malignant neoplasms, except for curatively treated:~* Basal and squamous cell carcinoma of the skin;~* Carcinoma in situ of the cervix.~* Patients with a prior malignancy diagnosed more than 10 years prior to randomisation may enter the study. Patients must have been curatively treated with surgery alone. Radiation therapy or systemic therapy (chemotherapy or endocrine) are NOT permitted. Prior diagnoses of breast cancer or melanoma are excluded.~* Diagnosis of inflammatory breast cancer;~* Bilateral cancer;~* This criterion has been deleted from the protocol Version 1. Patients with multi-focal cancer are no longer excluded.~* Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (≥180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic therapy with oxygen;~* Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety;~* Unresolved or unstable, serious adverse events from prior administration of another investigational drug;~* Active or uncontrolled infection;~* Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF;~* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;~* Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies);~* Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;~* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab or lapatinib or their excipients;~* Pregnant or lactating women;~* Concomitant use of CYP3A4 inhibitors or inducers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 Lapatinib (Type: EXPERIMENTAL): 1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
- Arm 2 Trastuzumab (Type: ACTIVE_COMPARATOR): 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
- Arm 3 Lapatinib plus Trastuzumab (Type: EXPERIMENTAL): 1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).